Live market news
Stocks
PYPD

PolyPid Ltd.

PYPDStockUnited States

See in Charts

Latest news on PYPDranked by Oyticker for market impact

45Impact
Neutral1 Oct 2026 · 12:56 UTC · Europe · Medium term
PolyPid Regains European D-PLEX₁₀₀ Rights from ADVANZ PHARMA
PolyPid (PYPD) has terminated its 2022 exclusive European distribution agreement with ADVANZ PHARMA and regained direct commercialization rights for D-PLEX₁₀₀ in Europe.
PYPDBiopharmaceuticalsHealthcare

SEC filings

What PYPD filed

All its filings

28 Oct 2026
Report of a foreign company (opens the document on sec.gov)6-K
1 Oct 2026
Report of a foreign company (opens the document on sec.gov)6-K
1 Oct 2026
Report of a foreign company (opens the document on sec.gov)6-K
12 Aug 2026
Report of a foreign company (opens the document on sec.gov)6-K
12 Aug 2026
Report of a foreign company (opens the document on sec.gov)6-K
29 Jul 2026
Report of a foreign company (opens the document on sec.gov)6-K
21 Jul 2026
Report of a foreign company (opens the document on sec.gov)6-K
15 Jul 2026
Report of a foreign company (opens the document on sec.gov)6-K
10 Jun 2026
Report of a foreign company (opens the document on sec.gov)6-K
1 Jun 2026
Report of a foreign company (opens the document on sec.gov)6-K
13 May 2026
Report of a foreign company (opens the document on sec.gov)6-K

From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on PYPDranked by Oyticker for market impact

PolyPid Regains European D-PLEX₁₀₀ Rights from ADVANZ PHARMA

What PYPD filed